KBL Merger Corp. IV

Status: Closed Deal

U=S+W+R W=S/2@11.5 R=S/10

IPO Proceeds, $M	$115.00M
IPO Date	Jun 2, 2017
CEO	Marlene Krauss, M.D.
Left Lead	Ladenburg Thalmann
IPO Cash in Trust	101.4%
SPAC Tenor	18+3+3+3+3+4+3+4
IPO Sector	Healthcare Healthcare and related wellness
IPO Geography	Global
Target Company	180 Life Sciences
Deal Announced	Jul 26, 2019
Deal Size, $M	$242.90M
Deal Sector	Healthcare
Deal Geography	US/Canada
SEC Filings	www.sec.gov
Approval Vote	Oct 26, 2020
Amendment Vote	TBD
Closing Date	Nov 6, 2020

Formerly KBLM ATNF ATNFW

Price	$1.46 $0.00
Last closing price	$1.47
H/L, today	$1.40 / $1.48
H/L, 52-week	$0.36 / $11.14
Volume, today	55,068
Volume, 3-month avg.	N/A

Price
Volume, today
Volume, 3-month avg.	N/A

Price	$0.01
Last closing price	$0.01
High/low price, today	$0.01 / $0.01
High/low price, 52-week	$0.00 / $0.15
Volume, today	28,978
Volume, 3-month avg.	N/A

Price
Volume, today
Volume, 3-month avg.	N/A

No credit card required

Structure and cap table
5 directors & officers
47 filings and events
5 underwriters

Structure

Sign in to view structure, cap table, and calendar of events.

Team

Name	Age	Title
Marlene Krauss, M.D.	71	CEO & Director
Joseph A. Williamson	63	COO & Director
George Hornig	62	Chairman of the Board
Andrew Sherman	47	Director
Sherrill Neff	64	Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors

Underwriters
Ladenburg Thalmann	Joint BR	4,700,000	units
B. Riley FBR	Joint BR	2,282,500
FBR Capital Markets	Joint BR	2,282,500
Chardan		435,000
I-Bankers Securities		300,000
		10,000,000	units
	Up-Front UW fee	2.50	%
	Deferred UW fee	3.50	%

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings


Jun 2, 2017	IPO Prospectus
Jun 13, 2017	8-K with fully audited balance sheet
Jun 26, 2017	8-K reflecting full exercise of underwriter over-allotment option Sign In to view filing content.
Nov 15, 2018	8-K announcing first annual meeting of stockholders Sign In to view filing content.
Nov 16, 2018	8-K announcing entrance into several non-binding letters of intent Sign In to view filing content.
Nov 28, 2018	DEF14A Definitive Proxy for annual meeting of shareholders Sign In to view filing content.
Feb 8, 2019	PRE14A Preliminary Proxy for shareholder meeting to extend charter Sign In to view filing content.
Feb 20, 2019	DEF14A Definitive Proxy for shareholder meeting to extend charter Sign In to view filing content.
Mar 8, 2019	8-K announcing approval of charter extension Sign In to view filing content.
Apr 16, 2019	8-K announcing non-binding term sheet for business combination with a private company Sign In to view filing content.
May 9, 2019	PRE14A Preliminary proxy for shareholder meeting to extend charter Sign In to view filing content.
May 14, 2019	8-K announcing non-binding term sheet to acquire CannBioRx Sign In to view filing content.
May 16, 2019	8-K with CannBioRX investor presentation Sign In to view filing content.
May 20, 2019	DEF14A Definitive Proxy for extension meeting Sign In to view filing content.
Jun 6, 2019	8-K with extension meeting results Sign In to view filing content.
Jul 26, 2019	Press Release announcing business combination with CannBioRx Sign In to view filing content.
Jul 26, 2019	8-K with CannBioRx business combination agreement details Sign In to view filing content.
Oct 31, 2019	PRE14A Preliminary proxy for shareholder meeting to extend charter Sign In to view filing content.
Nov 9, 2019	DEF14A Definitive Proxy for extension meeting Sign In to view filing content.
Nov 12, 2019	S-4 registration statement containing preliminary proxy for CannBioRx business combination Sign In to view filing content.
Dec 6, 2019	8-K with extension meeting results Sign In to view filing content.
Dec 12, 2019	8-K with updated investor presentation Sign In to view filing content.
Feb 3, 2020	8-K with Amendment #1 to CannBioRx business combination agreement Sign In to view filing content.
Feb 10, 2020	S-4/A Amendment #1 to registration statement containing preliminary proxy for CannBioRx business combination Sign In to view filing content.
Mar 10, 2020	PRE14A Preliminary proxy for charter extension meeting Sign In to view filing content.
Mar 24, 2020	DEF14A Definitive proxy for charter extension meeting Sign In to view filing content.
Apr 8, 2020	8-K with extension meeting results Sign In to view filing content.
Jun 18, 2020	PRE14A Preliminary proxy for shareholder meeting to extend charter Sign In to view filing content.
Jun 29, 2020	PR announcing successful completion of bridge financing Sign In to view filing content.
Jun 30, 2020	DEF14A Definitive proxy for shareholder meeting to extend charter Sign In to view filing content.
Jul 2, 2020	8-K announcing Securities Purchase Agreement Sign In to view filing content.
Jul 13, 2020	8-K announcing approval of charter extension Sign In to view filing content.
Aug 13, 2020	8-K with Amendment #2 to CannBioRx business combination agreement Sign In to view filing content.
Aug 28, 2020	S-4/A Amendment #2 to registration statement containing preliminary proxy for CannBioRx business combination Sign In to view filing content.
Sep 14, 2020	8-K announcing Securities Purchase Agreement Sign In to view filing content.
Oct 7, 2020	8-K announcing 180 Life Sciences new board of directors Sign In to view filing content.
Oct 9, 2020	424B3 Definitive proxy/prospectus for 180 Life Sciences transaction Sign In to view filing content.
Oct 12, 2020	PR announcing date for meeting to approve 180 Life Sciences business combination Sign In to view filing content.
Oct 13, 2020	425 with updated investor presentation Sign In to view filing content.
Oct 19, 2020	S-1 Registration statement for the resale of stock in connection with 180 Life Sciences business combination
Oct 23, 2020	8-K announcing change of 180 Life Sciences approval meeting date Sign In to view filing content.
Nov 2, 2020	424B4 Prospectus for the resale of stock in connection with 180 Life Sciences business combination
Nov 6, 2020	8-K announcing approval of 180 Life Sciences business combination Sign In to view filing content.
Nov 6, 2020	CA Corporate Action Alert announcing closing of 180 Life Sciences business combination Sign In to view filing content.
Nov 12, 2020	Super 8-K for closing of 180 Life Sciences business combination Sign In to view filing content.
Jul 20, 2021	S-1 Post-closing registration statement Sign In to view filing content.
Jul 27, 2021	EFFECT Effectiveness of post-closing registration statement Sign In to view filing content.